Abstract
Mild cognitive impairment (MCI) is considered as the transitional phase between normal cognitive aging and Alzheimer’s disease (AD). Nevertheless, trajectories of cognitive decline vary considerably among individuals with MCI. To address this heterogeneity, subtyping approaches have been developed, with the objective of identifying more homogenous subgroups and ultimately improving prognostic outcomes. To date, subtyping of MCI has been based primarily on cognitive performance measures, often resulting in indistinct boundaries between the proposed subgroups and limited validity. The degree to which markers of neurodegeneration such as brain atrophy can be used to subtype MCI into biologically and clinically meaningful subgroups remains unclear. Here we introduce and validate a data-driven subtyping method for MCI based solely upon measures of atrophy derived from structural magnetic resonance imaging (MRI). We trained a dense convolutional neural network to differentiate between patients with AD and age-matched cognitively normal (CN) subjects based on whole brain MRI features. We then deployed the trained model to classify individuals with MCI, as MCI-CN or MCI-AD, based on the degree to which their whole brain gray matter volume resembles CN-like or AD-like patterns. We subsequently validated the model-based subgroups using cognitive, clinical, fluid biomarker, and molecular neuroimaging data. Namely, we observed marked differences between the MCI-CN and MCI-AD groups in baseline and longitudinal cognitive and clinical rating scales, disease-free survival, cerebrospinal fluid (CSF) levels of amyloid beta and tau, fluorodeoxyglucose (FDG) and amyloid PET. Overall, the results suggest that patterns of atrophy in MCI are sufficiently distinct and heterogeneous, and can thus be used to subtype individuals into biologically and clinically meaningful subgroups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R01AG062590. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study involved analysis of de-identified data and was exempt from the local Institutional Review Board (UNC Chapel Hill, IRB number: 19-1090)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in analysis or writing of this article. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Data Availability
All data associated with this study are in the paper or the Supplementary Materials. All raw data including MRI, CSF, and cognitive scores are available through the ADNI data archive (http://adni.loni.ucs.edu/).
